ATE348608T1 - Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne - Google Patents

Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne

Info

Publication number
ATE348608T1
ATE348608T1 AT04075431T AT04075431T ATE348608T1 AT E348608 T1 ATE348608 T1 AT E348608T1 AT 04075431 T AT04075431 T AT 04075431T AT 04075431 T AT04075431 T AT 04075431T AT E348608 T1 ATE348608 T1 AT E348608T1
Authority
AT
Austria
Prior art keywords
migraines
hiv
colon cancer
receptor ligand
use against
Prior art date
Application number
AT04075431T
Other languages
English (en)
Inventor
Mark Bamford
Richard Howard Green
Richard Coles
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918745.2A external-priority patent/GB9918745D0/en
Priority claimed from GBGB9928437.4A external-priority patent/GB9928437D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE348608T1 publication Critical patent/ATE348608T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT04075431T 1999-08-10 2000-08-08 Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne ATE348608T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918745.2A GB9918745D0 (en) 1999-08-10 1999-08-10 Medical uses
GBGB9928437.4A GB9928437D0 (en) 1999-12-01 1999-12-01 Medical uses

Publications (1)

Publication Number Publication Date
ATE348608T1 true ATE348608T1 (de) 2007-01-15

Family

ID=26315833

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04075431T ATE348608T1 (de) 1999-08-10 2000-08-08 Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne
AT00956408T ATE272398T1 (de) 1999-08-10 2000-08-08 Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00956408T ATE272398T1 (de) 1999-08-10 2000-08-08 Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz

Country Status (8)

Country Link
US (1) US6861441B1 (de)
EP (2) EP1202730B1 (de)
JP (1) JP2003506404A (de)
AT (2) ATE348608T1 (de)
AU (1) AU6836200A (de)
DE (2) DE60032524T2 (de)
ES (2) ES2274378T3 (de)
WO (1) WO2001010426A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AU3445100A (en) * 2000-03-24 2001-10-08 Pharmagene Lab Ltd Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0031295D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
DE60222168T2 (de) * 2001-10-31 2008-05-15 Medical Research Council Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
EP1563846B1 (de) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogene reparaturfaktoren herstellende promoter
GB0302094D0 (en) * 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
CN1946391A (zh) * 2004-04-20 2007-04-11 辉瑞产品公司 包含α－2－δ配体的组合
UY30121A1 (es) * 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
GB0602900D0 (en) * 2006-02-13 2006-03-22 Glaxo Group Ltd Novel Compounds
GB0615111D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel compounds
GB0616498D0 (en) * 2006-08-18 2006-09-27 Glaxo Group Ltd Novel compounds
GB0620619D0 (en) * 2006-10-17 2006-11-29 Glaxo Group Ltd Novel compounds
GB0623203D0 (en) * 2006-11-21 2007-01-03 Glaxo Group Ltd Novel compounds
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
GB0715463D0 (en) * 2007-08-08 2007-09-19 Glaxo Group Ltd Novel compounds
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CA2754702C (en) * 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
CN102770458A (zh) * 2009-12-02 2012-11-07 阿塞勒隆制药公司 用于增加Fc融合蛋白的血清半寿期的组合物和方法
EP2718328A4 (de) 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
US20150004175A1 (en) * 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
EP2846793A1 (de) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur vorbeugung oder behandlung von chronisch obstruktiver lungenerkrankung
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
CN105939713A (zh) * 2014-03-06 2016-09-14 阿莱塔纳治疗学股份有限公司 格拉匹纶组合物及其使用方法
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH574409A5 (en) * 1972-09-29 1976-04-15 Sandoz Ag Benzo(f)isoindoline derivs - with antidepressant and analgesic activity
IL62734A (en) * 1980-04-30 1985-10-31 Glaxo Group Ltd Aminocyclopentane alkenoic acids and esters,their preparation and pharmaceutical formulations
US4618683A (en) * 1982-06-01 1986-10-21 Abbott Laboratories Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives
NO872963L (no) * 1986-07-29 1988-02-01 Glaxo Group Ltd Isokinolinderivater.
EP0501579A1 (de) 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalinlactone als Inhibitoren der Leukotrien-Biosynthese
EP0520573A1 (de) * 1991-06-27 1992-12-30 Glaxo Inc. Derivate von cyclischen Imiden
JPH10500402A (ja) 1994-04-29 1998-01-13 武田薬品工業株式会社 縮合複素環化合物またはその塩、その製造法および用途
BR9509985A (pt) * 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors

Also Published As

Publication number Publication date
JP2003506404A (ja) 2003-02-18
EP1442744B1 (de) 2006-12-20
WO2001010426A2 (en) 2001-02-15
ES2225199T3 (es) 2005-03-16
EP1442744A2 (de) 2004-08-04
ES2274378T3 (es) 2007-05-16
EP1442744A3 (de) 2005-04-06
ATE272398T1 (de) 2004-08-15
EP1202730A2 (de) 2002-05-08
WO2001010426A3 (en) 2001-12-20
DE60032524T2 (de) 2007-07-05
DE60012751D1 (de) 2004-09-09
DE60032524D1 (de) 2007-02-01
AU6836200A (en) 2001-03-05
US6861441B1 (en) 2005-03-01
EP1202730B1 (de) 2004-08-04
DE60012751T2 (de) 2005-01-20

Similar Documents

Publication Publication Date Title
DE60032524D1 (de) EP4 Rezeptor Ligand und Verwendung gegen neuropatischen Schmerzen, Colon Krebs, HIV und Migräne
DE60119397D1 (de) "2-Oxo-1-Pyrrolidinderivate und ihre pharmazeutische Verwendung"
ATE448226T1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
ATE350036T1 (de) Tetrahydroquinolin-derivate
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
HK1041256A1 (zh) 靛系双吲衍生物
ATE180468T1 (de) Anthranilsäure derivate
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
ATE278661T1 (de) Anthranilsäurederivate
PL377467A1 (pl) Aromatyczne związki jako środki przeciwzapalne, immunomodulujące i antyproliferacyjne
ATE295841T1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
ATE228518T1 (de) Amid derivate
DE60013994D1 (de) 1,2-Disubstituierte 1,4-Dihydro-4-oxochinolin-Verbindungen
DE69810960D1 (de) 2-phenoxyanilin-derivate
DE60043497D1 (de) 4-Substituierte-3,6-Anhydro-Galaktosederivate und ihre pharmazeutische Verwendung
ES2102772T3 (es) Compuesto citotoxico y antiviral.
DE69814563D1 (de) Pyrrolo-(3,2-b)pyridine und ihre Verwendung als 5-HT1F Agonisten
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
DE60210283D1 (de) 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
ATE252546T1 (de) 3-(3-hydroxyphenyl)-3-amino-propionamidderivate
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties